Monofree (Dexamethasone Phosphate)

Monofree (dexamethasone phosphate) is a glucocorticoid used to manage inflammatory eye conditions.

• Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery.
• Non‑infectious uveitis: suppresses intra‑ocular inflammation and helps prevent tissue damage.
• Allergic conjunctivitis: alleviates itching, redness and swelling caused by allergic reactions.

• Dexamethasone phosphate binds to intracellular glucocorticoid receptors in ocular tissues, forming a receptor‑ligand complex that translocates to the nucleus. This complex modulates gene transcription, decreasing the production of pro‑inflammatory cytokines and mediators while enhancing anti‑inflammatory protein expression, resulting in reduced ocular inflammation and immune response.

Adverse reactions may occur with ocular use of dexamethasone phosphate.

Common Side Effects

• Transient eye irritation or burning sensation.
• Mild conjunctival hyperemia.
• Temporary increase in intra‑ocular pressure.
• Blurred vision that resolves after discontinuation.
• Mild headache.

Serious or Rare Side Effects

• Persistent elevation of intra‑ocular pressure leading to glaucoma.
• Secondary ocular infections such as bacterial or fungal keratitis.
• Cataract formation with prolonged use.
• Severe allergic reaction with eyelid edema and erythema.
• Delayed wound healing after ocular surgery.

Use Monofree only under the direction of an eye care professional.

• Pregnancy: safety not established; avoid unless benefits outweigh risks.
• Breastfeeding: unknown; consider potential exposure to infant.
• Pre‑existing glaucoma or ocular hypertension: monitor intra‑ocular pressure closely.
• Long‑term therapy: limit duration to reduce risk of cataract or pressure rise.
• Store at room temperature: keep in original container, protect from light and moisture.

Dexamethasone phosphate may interact with other ocular or systemic agents.

Major Interactions (Avoid)

• Concurrent use of potent intra‑ocular steroids: risk of additive pressure increase.
• Anticholinergic eye drops: may reduce steroid absorption.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory eye drops: possible additive irritation.
• Systemic CYP3A4 inhibitors: may modestly increase systemic exposure.
• Antifungal eye preparations: monitor for reduced antifungal efficacy.